Ron Rye

495 total citations
8 papers, 383 citations indexed

About

Ron Rye is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Ron Rye has authored 8 papers receiving a total of 383 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Genetics. Recurrent topics in Ron Rye's work include Glioma Diagnosis and Treatment (2 papers), Brain Metastases and Treatment (2 papers) and Cancer Treatment and Pharmacology (2 papers). Ron Rye is often cited by papers focused on Glioma Diagnosis and Treatment (2 papers), Brain Metastases and Treatment (2 papers) and Cancer Treatment and Pharmacology (2 papers). Ron Rye collaborates with scholars based in United Kingdom, United States and Switzerland. Ron Rye's co-authors include John F. Smyth, Moira Stewart, Mark DeWitte, C. Sturgeon, David Propper, Melanie Mackean, Frances R. Balkwill, Uma Prabhakar, Charlie Gourley and Ewan Brown and has published in prestigious journals such as Journal of Clinical Oncology, Clinical Cancer Research and British Journal of Cancer.

In The Last Decade

Ron Rye

8 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ron Rye United Kingdom	6	158	121	119	90	71	8	383
Masayuki Ohno Japan	11	256 1.6×	264 2.2×	140 1.2×	40 0.4×	29 0.4×	18	508
Kuo‐Chang Wen Taiwan	12	102 0.6×	216 1.8×	81 0.7×	63 0.7×	43 0.6×	28	435
Pardeep Kaurah Canada	8	130 0.8×	182 1.5×	143 1.2×	26 0.3×	133 1.9×	10	423
Ahmed El‐Balat Germany	10	208 1.3×	118 1.0×	166 1.4×	66 0.7×	29 0.4×	34	426
Maria Corallo Italy	8	300 1.9×	182 1.5×	51 0.4×	106 1.2×	21 0.3×	11	455
Diana P. English United States	14	232 1.5×	140 1.2×	98 0.8×	49 0.5×	18 0.3×	24	447
Çiğdem Himmetoğlu Türkiye	11	109 0.7×	163 1.3×	45 0.4×	26 0.3×	143 2.0×	17	407
Hanna Sallinen Finland	14	95 0.6×	197 1.6×	172 1.4×	41 0.5×	27 0.4×	24	394
Judy Walls United States	9	114 0.7×	170 1.4×	110 0.9×	44 0.5×	40 0.6×	12	448

Countries citing papers authored by Ron Rye

Since Specialization

Citations

This map shows the geographic impact of Ron Rye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ron Rye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ron Rye more than expected).

Fields of papers citing papers by Ron Rye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ron Rye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ron Rye. The network helps show where Ron Rye may publish in the future.

Co-authorship network of co-authors of Ron Rye

This figure shows the co-authorship network connecting the top 25 collaborators of Ron Rye. A scholar is included among the top collaborators of Ron Rye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ron Rye. Ron Rye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

1.

Faluyi, Olusola Olusesan, Charlie Gourley, John F. Smyth, et al.. (2010). Higher incidence of isolated brain metastases in ovarian cancer patients with previous early breast cancer.. PubMed. 20(9). 1511–7. 5 indexed citations

2.

Capdevila, Jaume, Sally Clive, Josep Tabernero, et al.. (2009). Phase I study of the novel anticancer drug PM00104 as a 24-hour IV infusion every 3 weeks (q3w) in patients (pts) with advanced solid tumors or lymphoma. Journal of Clinical Oncology. 27(15_suppl). 2568–2568. 4 indexed citations

3.

Brown, Ewan, Kellie A. Charles, Susan Hoare, et al.. (2008). A clinical study assessing the tolerability and biological effects of infliximab, a TNF-α inhibitor, in patients with advanced cancer. Annals of Oncology. 19(7). 1340–1346. 140 indexed citations

4.

Smyth, John F., Charlie Gourley, Graeme E. Walker, et al.. (2007). Antiestrogen Therapy Is Active in Selected Ovarian Cancer Cases: The Use of Letrozole in Estrogen Receptor–Positive Patients. Clinical Cancer Research. 13(12). 3617–3622. 144 indexed citations

5.

Ironside, James W., et al.. (2002). The prognostic influence of bcl-2 in malignant glioma. British Journal of Cancer. 86(12). 1899–1904. 28 indexed citations

6.

Dawson, L., Duncan I. Jodrell, A. Bowman, et al.. (2000). A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. European Journal of Cancer. 36(18). 2353–2359. 33 indexed citations

7.

Bowman, A., Ron Rye, Alan V. Boddy, et al.. (1999). A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration. British Journal of Cancer. 79(5-6). 915–920. 12 indexed citations

8.

Gregor, Anna, R. Rampling, Matti Aapro, et al.. (1992). Phase II study of tauromustine in malignant glioma. European Journal of Cancer. 28(12). 1959–1962. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact